Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma Introduces Next-Gen High-Sensitivity Protein Detection Platform | Contract Pharma
Breaking News

MilliporeSigma Introduces Next-Gen High-Sensitivity Protein Detection Platform

New SMCxPRO technology offers high speed, high sensitivity for single molecule detection

MilliporeSigma has launched its newest high-sensitivity detection platform, SMCxPRO technology. It is designed to allow researchers to detect and quantify low-abundance biomarkers that traditional methods cannot measure. The instrument features a high-sensitivity detection system, with speed and accuracy, in a compact design. It will be available in the third quarter this year.

“MilliporeSigma’s newest innovation, SMCxPRO technology, is part of a suite of tools for detecting and characterizing, accelerating drug discovery and improving overall lab productivity,” said Jason Apter, head of research solutions strategic marketing and innovation, MilliporeSigma. “Detection of low-abundance biomarkers allows for quantitation of a new class of novel targets. We are committed to empowering researchers by providing the technologies needed to accelerate advancements in healthcare.”

Along with the new SMCxPRO technology, MilliporeSigma offers a wide range of solutions for biomarker discovery and novel target identification including its recently released Sanger CRISPR libraries that expand the company’s suite of gene editing tools.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters